The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Erythropoietin Therapy in Hematology

Indications, dosing, and risks of erythropoiesis stimulating agents

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Erythropoietin Therapy in Hematology?

Erythropoiesis stimulating agents are recombinant analogs of endogenous erythropoietin that bind erythroid progenitor receptors and increase red cell production. Approved indications include anemia of chronic kidney disease, chemotherapy associated anemia in non curative settings, and selected lower risk myelodysplastic syndromes with low endogenous erythropoietin.

Dosing targets a hemoglobin range that improves quality of life without exceeding twelve grams per deciliter, since higher targets increase cardiovascular and thrombotic events. Iron status must be optimized before therapy and during dose escalation, because functional iron deficiency limits response.

Adverse effects include hypertension, venous thromboembolism, increased red cell mass, seizures, pure red cell aplasia from neutralizing antibodies, and concerns regarding tumor progression in some malignancies. Therapy is withheld when target hemoglobin is reached and resumed at reduced dose if anemia returns.

Symptoms

Fatigue and dyspnea from anemia
Improved exercise tolerance with response
New or worsening hypertension on therapy
Headache or seizure during overcorrection
Loss of response in pure red cell aplasia

Risk Factors

Chronic kidney disease stages three to five
Active chemotherapy with non curative intent
Lower risk myelodysplastic syndrome with low erythropoietin
Recent venous thromboembolism
Uncontrolled hypertension

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • When hemoglobin falls below ten with symptoms
  • When transfusion dependence persists
  • When hypertension worsens on therapy
  • When thrombosis or seizure occurs
  • When response is lost despite iron repletion

Treatment Methods

01
Iron repletion before initiation
02
Subcutaneous or intravenous administration
03
Hemoglobin monitoring every two to four weeks
04
Target hemoglobin not exceeding twelve
05
Dose adjustment for response and side effects
06
Discontinuation when transfusion independence is achieved
07
Investigation for pure red cell aplasia in loss of response

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.